SEPTInvestingStart Free

XERS 8-K: Guidance raise

Xeris Biopharma

Filed with the SEC on · accession 0001867096-26-000114

XERS filed a 8-K (current report) with the SEC on Nov 5, 2026. Xeris Biopharma reported Q3 2026 total revenue of $107.2 million, up 44% year-over-year, driven by Recorlev net revenue growth of 93%. The stock moved +25.0% by the first close after the filing.

Summary of the filing

Xeris Biopharma reported Q3 2026 total revenue of $107.2 million, up 44% year-over-year, driven by Recorlev net revenue growth of 93%. The company raised full-year 2026 total revenue guidance to $395-$405 million and increased its 2030 revenue outlook to more than $1 billion from approximately $750 million.

For details, click here →How to read a 8-K →

Key details

Q3 2026 total revenue$107.2M
Q3 2026 Recorlev net revenue$71.5M
Q3 2026 net income$11.3M
Q3 2026 adjusted EBITDA$30.8M
Full-year 2026 total revenue guidance low end$395.0M
Full-year 2026 total revenue guidance high end$405.0M
2030 total revenue outlook$1.0B
IssuerXeris Biopharma Holdings, Inc.
Chairman and chief executive officerJohn Shannon

How XERS stock reacted

Close before

$10.46

Nov 4, 2026

First close after

+25.05%

$13.08

5 trading days

—

Since filing

—

✦ Ask GOAX AI about this filing — what it means for XERS, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for XERS?

Click here

Frequently asked questions

What did XERS file with the SEC on Nov 5, 2026?

XERS filed a 8-K (Guidance raise). Xeris Biopharma reported Q3 2026 total revenue of $107.2 million, up 44% year-over-year, driven by Recorlev net revenue growth of 93%. The company raised full-year 2026 total revenue guidance to $395-$405 million and increased its 2030 revenue outlook to more than $1 billion from approximately $750 million.

What does a guidance raise mean for XERS stock?

Guidance is the company’s own forecast. Investors price stocks on the future, so a raise or cut often moves the stock more than the past quarter’s numbers.

How do I read a 8-K?

A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

How did XERS stock react to this filing?

XERS closed at $10.46 before the filing and $13.08 on Nov 5, 2026 (+25.05%).

Other XERS SEC filings

Get alerts when XERS files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days
XERS overviewXERS analysisXERS newsLatest SEC filings